BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Sep 17, 2012
 |  BioCentury  |  Emerging Company Profile

KellBenx: Capturing fetal cells

KellBenx capturing fetal red blood cells to diagnose chromosomal disorders

KellBenx Inc. is developing prenatal diagnostics that it says will capture larger amounts of intact fetal DNA from a maternal blood sample, allowing the biotech to diagnose a wider range of genetic abnormalities than marketed products that the company says capture only small fractions of poor quality genetic material.

KellBenx's prenatal diagnostic uses a mAb against an antigen located only the surface of nucleated fetal red blood cells to capture the cells for diagnostic applications.

KellBenx licensed the technology from AdnaGen AG, a subsidiary of OncoVista Innovative Therapies Inc., in 2010. According to KellBenx co-founder and CEO Hassan Bennani, the technology was outside AdnaGen's focus on circulating tumor cell diagnostics.

A patent covering the technology describes an antibody that captures intact red blood cells that express transferrin receptor protein 1 (TFRC; TFR; CD71) but do not express CD45. Bennani said...

Read the full 717 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >